SCHEMBL6323947

SCHEMBL6323947

Cc1[nH]c(/C=C2\C(=O)Nc3cccc(-c4ccccc4F)c32)c(C)c1C(=O)N1CCN(C)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 4/20 0.54
KDR P35968 13/20 0.53
FLT1 P17948 4/20 0.53
FGFR1 P11362 10/20 0.52
PTK2B Q14289 2/20 0.52
MEN1 O00255 1/20 0.52
CCNE1 P24864 1/20 0.52
CDK2 P24941 1/20 0.52
RECQL P46063 1/20 0.52
KMT2A Q03164 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
FLT3 P36888 5/20 0.51
AURKB Q96GD4 4/20 0.51
PDGFRB P09619 9/20 0.49
EGFR P00533 1/20 0.49
PDGFRA P16234 1/20 0.49
ALK Q9UM73 4/20 0.47
RET P07949 4/20 0.47
ABL1 P00519 2/20 0.47
TLK2 Q86UE8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323956 1.00 MET (0.54) METKDRFLT1FGFR1PTK2B
SCHEMBL6319671 0.94 KDR (0.52) METKDRFLT1FGFR1PTK2B
SCHEMBL6324854 0.94 KDR (0.53) METKDRFLT1FGFR1PTK2B
SCHEMBL6321574 0.92 KDR (0.58) METKDRFLT1FGFR1PTK2B
SCHEMBL6327763 0.90 KDR (0.56) METKDRFLT1FGFR1PTK2B
SCHEMBL6323687 0.90 MET (0.56) METKDRFLT1FGFR1PTK2B
SCHEMBL6323692 0.90 MET (0.56) METKDRFLT1FGFR1PTK2B
SCHEMBL6324302 0.89 KDR (0.56) METKDRFLT1FGFR1PTK2B
SCHEMBL6324306 0.89 KDR (0.56) METKDRFLT1FGFR1PTK2B
SCHEMBL6327853 0.88 KDR (0.55) METKDRFLT1FGFR1PTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US claimed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US claimed
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 MET 501/4885KDR 819/4885FLT1 1811/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 MET 501/4885KDR 819/4885FLT1 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.